Health Security Act of 1993: Hearings Before the Committee on Labor and Human Resources, United States Senate, One Hundred Third Congress, First Session, on Examining the Administration's Proposed Health Security Act, to Establish Comprehensive Health Care for Every American, Teil 3

Cover

Im Buch

Andere Ausgaben - Alle anzeigen

Häufige Begriffe und Wortgruppen

Beliebte Passagen

Seite 16 - ... essential in the diagnosis of major infectious and environmental threats to health. (7) training and education of public health professionals -- essential to ensure a workforce capable of carrying out public health functions. The program fosters greater accountability to the federal government than has been realized previously for the definition and reporting of progress in achieving public health objectives. • Preventable Priority Health Problems. A second competitive grant program will provide...
Seite 206 - Price Regulation Of Drugs Would Slow Innovation Price regulation of pharmaceuticals would be particularly harmful. Studies show that price regulation of pharmaceuticals stifles innovation — which harms patients and increases overall healthcare costs. The US International Trade Commission, in a 1991 study of the pharmaceutical industry, stated, "The enactment of cost-containment programs, price controls, or both, on a national level often results in decreased levels of R&D spending in that these...
Seite 183 - This report focuses mainly on the economic side of the R&D process. Pharmaceutical R&D is an investment, and the principal characteristic of an investment is that money is spent today in the hopes of generating even more money in the future. Pharmaceutical R&D is a risky investment; therefore, high financial returns are necessary to induce companies to invest in researching new chemical entities.
Seite 177 - ... that anything could have sidetracked it. Yet we have to ask ourselves, if the project were beginning in an environment dominated by regulation and cost containment, would we pursue it? Fortunately I don't have to answer that question. Yet the fact remains, many similar questions are around the comer. Some of those questions will be basic ones involving choice. Recently Glaxo announced a five-year $15 million international research collaboration to find better treatments for tuberculosis. This...
Seite 149 - PL 95-471 and the proposed amendments. We are deeply indebted to all of you for the interest and concern you've shown toward Indian Education as a whole and for your special help to the tribally...
Seite 164 - SENATOR DODD Senator DODD. Thank you, Mr. Chairman. Let me begin by thanking you for holding this hearing...
Seite 204 - ... medicine*. The financial impact of any healthcare-reform plan on research-based pharmaceutical companies must be fully recognized — particularly in view of the substantial costs already imposed by the four new Federal laws. Several of the specific provisions in the Administration's healthcare-reform bill — including the provision for a Medicarerebate tax — would adversely affect patients, the prospects for saving healthcare dollars and one of America's most internationally competitive high-technology...
Seite 177 - While we are firmly committed to our anti-tense project, an environment in which our potential for return is limited would make these questions far more difficult. Such an environment would force yet other, perhaps more fundamental choices as well. If the exigencies of a regulated marketplace and the realities of business cause investments in innovation to slow or shrink, which project gets the funding? Would it be the one offering hope to cancer patients whose vomiting is so severe that many choose...
Seite 206 - Regulation of drug prices would be especially harmful because it would bias research towards low-risk, low-benefit new products. Heinz Redwood, an industry analyst, wrote in a recent study, "Price regulation causes drug industry decisionmakers to shorten their time horizons and to reduce the scientific risk inherent in their research projects.
Seite 112 - ... and treatments of significant potential benefit. Dr. Beck said he believes that Geisinger and other similar groups still have large opportunities to wring out expense. Increasingly important, he said, will be reliance on clinical guidelines that reflect research, done locally or nationally, on what sequences of tests and treatments yield the best results for particular conditions. Still, Dr. Beck said, "At some point there will be tradeoffs between cost and quality.